December 2nd 2024
The European Commission has approved ribociclib plus an aromatase inhibitor for patients with early breast cancer.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
September 1st 1996ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.
Mandated ABMT Coverage May Not Lead to More Procedures
September 1st 1996PHILADELPHIA--A Massachusetts study suggests that legislation requiring insurers and HMOs to cover high-dose chemotherapy/autologous bone marrow or stem cell transplantation for metastatic breast cancer does not lead to significant increases in the number of procedures performed.
Health Insurance: Coverage of Autologous Bone Marrow Transplantation for Breast Cancer
September 1st 1996Rapid advances in biomedical research and technology are producing a continuous stream of new, and often expensive, medical devices, drugs, and therapies. Health insurers' decisions about whether and when to provide coverage for these new
Study Advocates Breast Ultrasound Screening as an Adjunct to Mammography
August 1st 1996With improved instrumentation and scanning techniques, breast ultrasound screening is earning a prominent role in the detection of breast cancer in women with dense breasts when no lump is felt and no abnormalities are detected on the
NCI Says Long-Awaited Long Island Breast Cancer Study Now Underway
August 1st 1996BETHESDA, Md--The Long Island Breast Cancer Study Project, ordered by Congress in 1993, is now underway under the auspices of the NCI and the National Institute of Environmental Health Sciences. The study will attempt to determine whether pollutants (pesticides and other chemical irritants) are linked to the area's excessive breast cancer rates.
Practice Guidelines May Lead to Fewer Malpractice Suits
August 1st 1996PHILADELPHIA--At Long Beach Community Medical Center, the addition, in 1993, of a new radiation therapy facility and a new cancer center spurred the development of clinical pathways (or practice guidelines) for radiation therapy and breast cancer.
More Insurers Covering ABMT, Despite Lack of Efficacy Data
July 1st 1996WASHINGTON--A General Accounting Office (GAO) report has found that more insurers are now covering autologous bone marrow transplants (ABMT) for patients with breast cancer even though the treatment is expensive and the benefits are not proven.
Taxotere for Anthracycline Refractory Advanced Breast Cancer
July 1st 1996COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) is now available for treatment of patients with locally advanced or metastatic breast cancer that has progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy.
ODAC Recommends Approval of Aredia for Breast Cancer Bone Mets
July 1st 1996GAITHERSBURG, Md--The FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend approval of Ciba-Geigy Corp.'s Aredia (pamidronate disodium for injection) for the treatment of osteolytic bone metastases in breast cancer patients undergoing either chemotherapy or hormonal therapy.
Radiologist Most Likely Target in Breast Cancer Lawsuits
July 1st 1996DALLAS--In the last 5 years, radiologists have become the specialists most often sued over breast cancer diagnoses, said Cathy R. Bowerman, JD, MPH, of the Southfield, Michigan, firm of Siemion, Huckabay, Bodary, Padilla, Morganti, & Bowerman.
RODEO Breast MRI Promising in Lobular Cancer Diagnosis
July 1st 1996DALLAS--RODEO breast MRI proved significantly more accurate than mammography in determining the extent of lobular carcinoma and in characterizing the morphology of the disease, Steven E. Harms, MD, said at the American College of Radiology breast cancer symposium.
Defining the Role of Post-Mastectomy Radiotherapy: The New Evidence
July 1st 1996It is ironic that the issue of aggressive local therapy for breast cancer has re-emerged as a controversial issue in the early 1990s, almost 100 years after Halsted proposed this theory in the early 1890s [1]. Since that time, both survival and quality of life seemed to have improved for patients with breast cancer, due to more sophisticated and effective treatments. Nonetheless, as Drs. Pierce and Lichter point out in their article, the precise balance between the benefits and risks of aggressive local therapy still remains to be defined.
New Aromatase Inhibitor Compared With Megestrol in Advanced Breast Cancer
June 1st 1996Results of a phase III multicenter European study reported in a recent issue of the European Journal of Cancer demonstrate that anastrozole (Arimidex), a new aromatase inhibitor, in doses of 1 and 10 mg orally once daily, is an effective treatment for
BRCA2 Gene Mutations Linked to Ovarian Cancer Cases
June 1st 1996WASHINGTON--University of Pennsylvania researchers have obtained the first "conclusive" evidence linking mutations in the recently cloned BRCA2 breast cancer gene to ovarian cancer, a discovery they say indicates that inheritance plays a significantly greater role in the disease than previously thought.
Study Finds a Link Between Fatty Acid Ratios and Breast Cancer
June 1st 1996WASHINGTON--A study of European women suffering from breast cancer has raised the intriguing possibility that the ratio of omega-3 to omega-6 polyunsaturated fatty acids (PUFA) may provide a way to predict an increased risk of the malignancy.
Aggressive Follow-up of Early Cancer Questioned
June 1st 1996BALTIMORE--Intensive, laboratory-based follow-up programs for patients treated for early stage breast cancer do not enhance survival or reduce morbidity, said John H. Fetting, MD, at a symposium sponsored by Johns Hopkins Oncology Center, where he is co-director of the Breast Service.
Panel Reviews Management of Tamoxifen-Related Side Effects
June 1st 1996An expert panel of seven cancer researchers and a representative of the National Alliance of Breast Cancer Organizations (NABCO) came together at the San Antonio Breast Cancer Symposium for a roundtable discussion of the use of tamoxifen (Nolvadex), sponsored by PRR, Inc., publisher of Oncology News International, Primary Care & Cancer, and the journal ONCOLOGY.
Synthetic Retinoid May Protect Against Breast Cancer Recurrence in Younger Women
June 1st 1996WASHINGTON--Interim results from an on-going Italian chemopreven-tion trial of a synthetic retinoid show a "borderline significant" protective effect against contralateral breast cancer and, to a lesser degree, against ovarian cancer, but only in premenopausal women.
Estradiol SPECT Shows Promise in Spotting Early Breast Cancer
June 1st 1996DALLAS--Estradiol scans, currently being used in research for the diagnosis of early breast cancer (see illustration on page 1), have in some cases identified breast cancer 2 years prior to diagnosis by conventional means, such as mam-mography, physical examination, and ultrasound, David F. Preston, MD, said in an interview with Oncology News International.
Recent Advances in the Treatment of Refractory Advanced Breast Cancer
June 1st 1996The incidence of breast cancer has risen steadily over the past several decades. Breast cancer is second only to lung cancer as a cause of cancer deaths among women; 46,000 women died of breast cancer in the United States alone in 1995. Despite efforts to improve the survival of women with metastatic breast cancer with currently available chemotherapeutic agents, results remain disappointing. The primary use of such agents continues to be for palliation, not cure.
Combinations of New and Old Agents for Breast Cancer Treatment: Future Directions
June 1st 1996Several new agents undergoing clinical development appear to be effective and tolerable in the management of metastatic breast cancer. In recent years, a number of new and exciting combinations have been described, with an efficacy similar or, in some cases, apparently superior to that of standard chemotherapeutic regimens, such as FAC and CMF. The next several years will witness a large number of comparative clinical trials, the major purpose of which will be to establish the role of these new drugs and combinations in the management of metastatic breast cancer. Almost simultaneously, similar strategies will be pursued for adjuvant therapy for primary breast cancer, with the goal of improving the curative efficacy of current regimens. These prospects are exciting; however, enthusiasm must be tempered with the knowledge that long-term toxicity is always a distinct possibility. Therefore, the development of new combinations, especially in the setting of adjuvant chemotherapy, should follow a systematic, conservative strategy. [ONCOLOGY 10(Suppl):30-36, 1996]
Current Status of Salvage Chemotherapy for Refractory Advanced Breast Cancer
June 1st 1996The definition of refractory advanced breast cancer remains elusive. Because of different definitions of objective response, frequent lack of precision in defining the number of prior chemotherapies, and differing interpretations